riluzole oral suspension Tiglutik
Selected indexed studies
- Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. (Clin Ther, 2019) [PMID:31635890]
- Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. (Drug Des Devel Ther, 2017) [PMID:28053507]
- Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis. (Front Neurol, 2021) [PMID:34305774]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. (2023) pubmed
- Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. (2024) pubmed
- Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. (2019) pubmed
- Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. (2017) pubmed
- Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis. (2021) pubmed
- Introduction to the Supplement. (2026) pubmed
- Treatment continuity of amyotrophic lateral sclerosis with available riluzole formulations: state of the art and current challenges in a 'real-world' setting. (2025) pubmed
- The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe. (2023) pubmed
- Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study. (2018) pubmed
- Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. (2017) pubmed